CClinicalTrials.gg
Active, not recruitingNCT07321821Updated Jan 12, 2026

Fermented Garlic Lettuce Powder and Cognitive Function in Adults With Mild Cognitive Impairment

An interventional study of Garlic Lettuce Fermented Powder and Placebo in Mild Cognitive Impairment (MCI), sponsored by Pusan National University Yangsan Hospital. Active, not recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Pusan National University Yangsan Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2026, 8 months ago, but the record still lists the study as active, not recruiting.
  • Registered 3 months after the study started (first participant enrolled Sep 2025, registered Dec 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

"This study aims to investigate the cognitive and psychological changes in adults with mild cognitive impairment (K-MoCA scores between 16 and 23) following daily consumption of fermented garlic lettuce powder for 2 months

02

Conditions studied

  • Mild Cognitive Impairment (MCI)

Keywords

  • Fermented Garlic Lettuce Powder
  • Mild Cognitive Impairment
  • Psychological Outcome
  • Randomized Controlled Trial
03

In context

Cognitive Dysfunction

3,843 studies on the registry are indexed under Cognitive Dysfunction; 1,100 are open to participants now.

This study's enrollment of 60 is close to the median of 65 across 2,808 interventional studies indexed under Cognitive Dysfunction.

Browse Cognitive Dysfunction studies →

Lead sponsor

Pusan National University Yangsan Hospital is the lead sponsor of 106 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adults aged 19 years or older with K-MoCA scores between 16 and 23.
  • Individuals with sufficient vision and hearing to participate in the study without difficulty.
  • Participants who are currently taking medications or receiving treatments that may affect cognition and are able to maintain the same dosage and regimen throughout the study period.
  • Individuals who voluntarily agree to participate in the study and provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Individuals who have undergone vascular-related surgery within the past 6 months or gastrointestinal surgery that may affect absorption of the study product (excluding simple appendectomy or hernia repair).
  • Individuals with a clinically significant history of hypersensitivity to medications or dietary supplements.
  • Individuals with a history of alcohol or drug abuse.
  • Individuals unable to communicate effectively.
  • Individuals who have participated in more than two dietary supplement studies or clinical trials within the current year, or within the past 6 months.
  • Individuals deemed unable to participate safely or effectively in the study by the investigator.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Fermented Garlic Lettuce Powder

    Participants receive fermented garlic lettuce powder, administered orally as three tablets per day for 2 months (total of 180 tablets).

    Dietary Supplement: Garlic Lettuce Fermented Powder

  • Placebo comparator
    Placebo Tablet

    Participants take 1 placebo tablet daily for 2 months, totaling 60 tablets

    Other: Placebo

Interventions

  • Dietary supplementGarlic Lettuce Fermented Powder

    The Garlic Lettuce Fermented Powder tablets (intervention group) are taken 3 tablets daily for 2 months, totaling 180 tablets

  • OtherPlacebo

    Participants take 1 placebo tablet daily for 2 months, totaling 60 tablets

06

What researchers measure

Primary outcomes

  1. K-MoCA

    The Korean version of the Montreal Cognitive Assessment (K-MoCA) is a cognitive screening tool with scores ranging from 0 to 30, with higher scores indicating better cognitive function. The outcome measure is the change in K-MoCA score.

    Time frame: Assessments are performed at baseline and at 2 months.

Secondary outcomes

  1. SVLT

    The Seoul Verbal Learning Test (SVLT) is a neuropsychological assessment tool used to evaluate verbal memory performance. Scores range from 0 to 36, with higher scores indicating better memory function.

    Time frame: Assessments are performed at baseline and at 2 months.

  2. KCWS

    The Korean Color-Word Stroop Test (KCWS) is a neuropsychological assessment used to evaluate executive function and cognitive control. Performance is measured by the number of correct responses within 1- and 2-minute intervals, with higher scores indicating better cognitive function.

    Time frame: Assessments are performed at baseline and at 2 months.

  3. RCFT

    The Rey Complex Figure Test (RCFT) is a neuropsychological assessment used to evaluate visuospatial constructional ability and visual memory. Scores range from 0 to 36, with higher scores indicating better memory performance.

    Time frame: Assessments are performed at baseline and at 2 months.

  4. DST

    The Digit Span Test (DST) is a neuropsychological assessment used to evaluate attention and working memory. Scores range from 0 to 24, with higher scores indicating better concentration and attention.

    Time frame: Assessments are performed at baseline and at 2 months.

  5. COWAT

    The Controlled Oral Word Association Test (COWAT) is a neuropsychological assessment used to evaluate verbal fluency and executive function. Scores range from 0 to 27, with higher scores indicating better verbal fluency, executive function, attention, and problem-solving abilities.

    Time frame: Assessments are performed at baseline and at 2 months.

  6. BDI

    The Beck Depression Inventory (BDI) is a self-report questionnaire used to assess the severity of depressive symptoms. Each item is scored from 0 to 3, with total scores ranging from 0 to 63, where higher scores indicate more severe depressive symptoms.

    Time frame: Assessments are performed at baseline and at 2 months.

  7. EQ-5D

    The EuroQol-5 Dimension (EQ-5D) is a standardized instrument for measuring health-related quality of life. Scores range from 0 to 100, with lower scores indicating better perceived health status and higher scores reflecting more severe health problems.

    Time frame: Assessments are performed at baseline and at 2 months.

  8. MFS

    The Multidimensional Fatigue Scale (MFS) is a self-report questionnaire used to assess fatigue across multiple dimensions. Each dimension is rated from 0 to 20, with a total score ranging from 0 to 100. Lower scores indicate less fatigue, while higher scores reflect more severe fatigue.

    Time frame: Assessments are performed at baseline and at 2 months.

  9. PWI-SF

    The Psychological Well-Being Index-Short Form (PWI-SF) is a self-report questionnaire used to assess psychological well-being. Each dimension is rated from 0 to 20, with total scores ranging from 0 to 54, where higher scores indicate better psychological well-being, life satisfaction, and emotional stability.

    Time frame: Assessments are performed at baseline and at 2 months.

  10. LSEQ

    The Leeds Sleep Evaluation Questionnaire (LSEQ) is a self-report instrument used to assess subjective sleep quality. Scores are based on a scale from 0 to 100, with higher scores indicating better sleep quality and lower scores reflecting greater sleep disturbance.

    Time frame: Assessments are performed at baseline and at 2 months.

07

Study locations

1 site
  • Pusan National University Yangsan Hospital
    Yangsan, Gyeongsangnam-do, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07321821
Lead sponsor
Pusan National University Yangsan Hospital
Responsible party
Yong-il Shin (Professor, Pusan National University Yangsan Hospital) — Principal investigator
First posted
Jan 7, 2026
Start date
Sep 19, 2025
Primary completion
Jan 21, 2026 (estimated)
Completion
Jan 21, 2026 (estimated)
Last update
Jan 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion